Core Insights - Genprex, Inc. has announced positive preclinical data for its diabetes gene therapy candidate GPX-002, presented at the 2025 American Diabetes Association Scientific Session, utilizing a non-viral lipid nanoparticle delivery system that may allow for repeat dosing [1][2] Group 1: Research and Development - The research indicates that Genprex is pioneering the use of lipid nanoparticles for direct infusion into the pancreatic duct, which could enhance the delivery of gene therapy for diabetes [2] - The study evaluated nine lipid nanoparticles for their efficiency in transfecting isolated mouse Islets of Langerhans, with two specific nanoparticles showing high transfection efficiency [4] - The selected lipid nanoparticle demonstrated 100 times more luciferase activity in the pancreas compared to other organs, indicating a targeted approach to transfection [5] Group 2: Product Information - GPX-002 is being developed for both Type 1 and Type 2 diabetes, aiming to transform alpha cells into functional beta-like cells in Type 1 diabetes and rejuvenate exhausted beta cells in Type 2 diabetes [6][7] - The innovative approach involves administering an adeno-associated virus (AAV) vector containing specific genes directly into the pancreatic duct, which can be performed via routine endoscopy [7] Group 3: Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing advanced technologies to deliver disease-fighting genes [8] - The company collaborates with leading institutions to advance its pipeline of gene therapies, including its oncology program that employs a systemic, non-viral delivery system [8]